BioCentury
ARTICLE | Clinical News

Enbrel etanercept: Data

June 17, 2013 7:00 AM UTC

Researchers at the Department of Veterans Affairs and colleagues reported data from the double-blind, U.S. and Canadian RACAT trial in 353 RA patients with active disease despite methotrexate therapy showing that initial therapy with once-weekly 50 mg Enbrel as an add-on to methotrexate was non-inferior to initial therapy with the generics sulfasalazine and hydroxychloroquine as an add-on to methotrexate on the primary endpoint of reducing mean DAS28 score from baseline to week 48 (2.3 vs. 2.1 points, p=0.002 for non-inferiority). The non-inferiority margin was 0.6 points. Both arms led to significant reductions in mean DAS28 score at week 24 compared to baseline (2.1 points for the Enbrel arm and 1.8 points for the generics arm, p=0.001 for both). ...